Bluebird puts €1.57m price on gene therapy Zynteglo - PMLiVE
FDA Approves Bluebird's $2.8 Million Gene Therapy for Rare Blood Disease - WSJ
FDA Approves $2.8 million Gene Tx - Zynteglo - Anton Health
bluebird bio's Zynteglo gene therapy receives FDA approval
FDA approves bluebird bio's Zynteglo gene therapy for beta thalassemia; shares up 7% | Seeking Alpha
bluebird claims first approval for gene therapy Zynteglo in EU -
Somerville gene therapy firm bluebird bio nabs win with first FDA approval following split - Boston Business Journal
SEC Filing - bluebird bio, Inc.
Bluebird wins U.S. approval for gene therapy for beta thalassemia - STAT
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions | Business Wire
FDA approves bluebird bio's Zynteglo for beta-thalassemia - BIO.News
bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies - Pharmaceutical Technology
bluebird bio Launches Gene Therapy for Severe Blood Disorder in Germany | North Carolina Biotechnology Center
bluebird bio gets CHMP nod for gene therapy Zynteglo | Pharmaphorum
SEC Filing - bluebird bio, Inc.
bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
Potential blockbusters make a splash on market entry - Clarivate
Bluebird Bio CEO defends $1.8 million price tag for new gene therapy
Bluebird bio's gene therapy Zynteglo could have high price tag defense in beta thalassemia - Pharmaceutical Technology
Zynteglo: Gene Therapy for Beta-thalassemia • BioPharma Media
Bluebird Bio Withdraws Zynteglo From Germany Over Pricing :: Pink Sheet
NEW | Bluebirdbio Releases Resources For Patients On Gene Therapy Zynteglo® – TIF
NICE turns down bluebird bio's gene therapy Zynteglo - PMLiVE
blue-ex992_54.htm
ICER Draft Evidence Report on Bluebird Gene Therapy Zynteglo Finds It Provides Value at $2.1 Million - Global Genes
